MDXG · XBRL financial data

Mimedx Group financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (MDXG's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	248,234	258,615	267,841	321,477	348,879	418,630
Cost of goods and services sold	39,330	43,283	48,316	54,634	60,073	73,013
Gross profit	208,904	215,332	219,525	266,843	288,806	345,617
Research and development	11,715	17,344	22,829	12,665	12,341	15,097
Selling, general and administrative	181,022	198,359	208,789	211,124	225,087	266,194
General and administrative	—	—	57,446	49,291	49,525	56,513
Operating income (loss)	(45,398)	(5,035)	(24,971)	37,116	58,865	63,887
Interest income	—	—	32	118	2,932	4,716
Interest expense	—	—	5,048	6,575	3,938	1,783
Other income (expense)	(3)	(23)	(4)	(26)	(565)	(558)
Income tax expense (benefit)	(12,259)	247	206	(36,806)	15,296	17,684
Net income (loss)	(49,284)	(10,285)	(30,197)	58,228	42,419	48,578
Earnings per share, basic USD per share	(0.77)	(0.15)	(0.33)	0.40	0.29	0.33
Earnings per share, diluted USD per share	(0.77)	(0.15)	(0.33)	0.37	0.28	0.32
Weighted average shares, basic thousands of shares	108,257	110,353	112,909	116,496	146,979	147,793
Weighted average shares, diluted thousands of shares	108,257	110,353	112,909	145,962	149,049	149,725

Fiscal years (MDXG's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	95,812	87,083	65,950	82,000	104,416	166,121
Accounts receivable	35,423	40,353	43,084	53,871	55,828	75,707
Inventory	10,361	11,389	13,183	21,021	23,807	25,340
Prepaid and other current assets	5,605	—	—	—	—	—
Total current assets	160,617	148,523	134,198	164,261	191,886	277,471
Property and equipment, net	11,437	—	—	—	—	—
Right-of-use asset	3,623	4,696	3,400	2,132	5,606	4,344
Goodwill	19,976	19,976	19,976	19,441	19,441	19,441
Total assets	202,032	187,929	171,430	239,047	263,915	342,653
Accounts payable	8,765	7,385	8,847	9,048	7,409	14,528
Accrued liabilities	30,460	9,812	11,024	9,361	9,012	11,383
Current portion of long-term debt	0	—	—	1,000	1,000	1,500
Total current liabilities	59,162	42,357	43,557	46,008	45,595	64,266
Long-term debt	47,697	48,127	48,594	48,099	17,830	16,467
Lease liability, non-current	2,960	3,812	2,381	893	4,705	3,245
Total liabilities	110,614	95,353	96,924	96,330	70,808	86,105
Accumulated deficit	(151,424)	(161,709)	(191,906)	(133,678)	(91,259)	(42,681)
Total stockholders' equity	(150)	82	(17,988)	142,717	193,107	256,548
Total liabilities and equity	202,032	187,929	171,430	239,047	263,915	342,653
Common shares outstanding (cover page) thousands of shares	111,261	112,360	114,083	146,958	147,366	148,567

Fiscal years (MDXG's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(49,284)	(10,285)	(30,197)	58,228	42,419	48,578
Stock-based compensation	15,357	14,757	12,666	16,959	16,933	16,396
Depreciation and amortization	—	—	—	3,427	6,041	14,881
Net cash from operating activities	(30,263)	(1,982)	(17,893)	26,775	66,198	74,003
Purchases of property and equipment	—	3,218	1,514	1,987	—	—
Net cash from investing activities	(4,555)	(3,395)	(2,660)	(2,155)	(9,583)	(6,886)
Share repurchases	900	0	0	9,515	0	0
Net cash from financing activities	61,561	(3,352)	(580)	(8,570)	(34,199)	(5,412)
Net change in cash	26,743	(8,729)	(21,133)	16,050	22,416	61,705

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Mimedx Group	120,791	62,283	3,919*	145.9M	—	Q3 FY26 10-QSep 30, 2026
Embecta	214,700	271,700	41,800*	56.7M	—	Q3 FY26 10-QJun 30, 2026
Heartflow	34,362	64,082	(8,577)*	87.0M	19.0 quarters	Q2 FY26 10-QJun 30, 2026
SI-BONE	35,311	55,704	5,940*	45.1M	—	Q3 FY26 10-QSep 30, 2026
Beta Bionics	81,551	35,505	(12,287)*	54.4M	13.0 quarters	Q3 FY26 10-QSep 30, 2026
Kestra Medical Technologies	68,558	30,971	(32,295)	59.6M	4.9 quarters	Q1 FY26 10-QJul 31, 2026
Biolife Solutions	23,997	not reported	6,348*	48.9M	—	Q2 FY26 10-QJun 30, 2026
Cadre Holdings	53,984	207,126	22,131*	42.8M	—	Q2 FY26 10-QJun 30, 2026
Avanos Medical	65,600	182,200	(12,300)	46.8M	5.3 quarters	Q1 FY26 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.